Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) diseases. The Company was established by experienced specialty pharmaceutical executives with a successful track record of acquiring, developing, registering, and marketing pharmaceutical products in the US.
Evoke has concentrated on the gastroenterology field due to the significant unmet medical needs, the opportunity to improve the delivery of existing products and the focused physician base. Despite the relatively large number of patients suffering from GI diseases and disorders, there are only about 12,000 gastroenterologists in the U.S. Each year, these physicians conduct over 31 million patient visits and write almost 40 million prescriptions. GI diseases and disorders may limit the absorption of current oral therapies reducing their effectiveness.
Evoke received FDA-approval for GIMOTI, a novel formulation of metoclopramide, designed to provide systemic delivery of drug through nasal administration. GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Evoke intends to commercialize GIMOTI, with its partner EVERSANA Life Sciences in the fourth quarter of 2020.